US Patent

US11865179 — Progesterone formulations having a desirable PK profile

Composition of Matter · Assigned to TherapeuticsMD Inc · Expires 2032-11-21 · 7y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects formulations of progesterone that have a desirable pharmacokinetic profile, allowing for reduced administration amounts while maintaining benefits.

USPTO Abstract

This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.

Drugs covered by this patent

Patent Metadata

Patent number
US11865179
Jurisdiction
US
Classification
Composition of Matter
Expires
2032-11-21
Drug substance claim
Yes
Drug product claim
Yes
Assignee
TherapeuticsMD Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.